Clinical Trials / Research Studies
Other Neurofibromatosis Trials

Other Neurofibromatosis Trials

NF114: Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

  • Ages: 1 Year to 8 Years

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in cl ...More

NF119: A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 (INSPIRE-NF1)

  • Ages: 16 Years and older

The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. NF119: A Phase 2, Open-Label, Single Arm, Non-Controlled, Single-S ...More